Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
SHSE:603676's PEG Ratio is ranked better than 84.57% of 350
companies
in the Drug Manufacturers industry
Industry Median: 1.655
vs SHSE:603676: 0.58
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Xizang Weixinkang Pharmaceutical Co (SHSE:603676) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Xizang Weixinkang Pharmaceutical Co PEG Ratio Related Terms
Xizang Weixinkang Pharmaceutical Co PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xizang Weixinkang Pharmaceutical Co PEG Ratio Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Xizang Weixinkang Pharmaceutical Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xizang Weixinkang Pharmaceutical Co PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Xizang Weixinkang Pharmaceutical Co's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Xizang Weixinkang Pharmaceutical Co's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Xizang Weixinkang Pharmaceutical Co (SHSE:603676) has a PEG Ratio of 0.58 as of Jul. 30, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Xizang Weixinkang Pharmaceutical Co and its competitors. This is near median its historical median of 0.54. Over the past decade, Xizang Weixinkang Pharmaceutical Co's PEG Ratio has ranged from 0.29 to 16.22. According to the industry distribution chart, Xizang Weixinkang Pharmaceutical Co ranks #54 out of 350 companies in the Drug Manufacturers industry, placing it in the top 15.4%.
Is Xizang Weixinkang Pharmaceutical Co's PEG Ratio too high?
Xizang Weixinkang Pharmaceutical Co's current PEG Ratio of 0.58 is near median its 10-year median of 0.54. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 16.22. The Drug Manufacturers industry median PEG Ratio is 1.66. Xizang Weixinkang Pharmaceutical Co's value of 0.58 is 65% below this industry median. Based on the distribution chart, Xizang Weixinkang Pharmaceutical Co ranks #54 out of 350 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Xizang Weixinkang Pharmaceutical Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Xizang Weixinkang Pharmaceutical Co's PEG Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Xizang Weixinkang Pharmaceutical Co ranks #54 out of 350 companies for PEG Ratio. This places Xizang Weixinkang Pharmaceutical Co in the top 15% of its industry — outperforming the majority of peers. The industry median PEG Ratio is 1.66. Xizang Weixinkang Pharmaceutical Co's value of 0.58 is 65% below this benchmark. Historically, Xizang Weixinkang Pharmaceutical Co's own PEG Ratio has ranged from 0.29 to 16.22 over the past decade. While the company's 10-year median is 0.54 vs. the industry median of 1.66, Xizang Weixinkang Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.66, based on 350 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xizang Weixinkang Pharmaceutical Co's current PEG Ratio of 0.58 is 65% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Xizang Weixinkang Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xizang Weixinkang Pharmaceutical Co's current PEG Ratio is 0.58, which is near median its own 10-year median of 0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xizang Weixinkang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Xizang Weixinkang Pharmaceutical Co (SHSE:603676) is currently considered Fairly Valued. The stock's GF Value™ is ¥8.93, compared to a current price of ¥8.78 — trading 1.7% below its estimated fair value. The current PEG Ratio is 0.58, which is near median its 10-year median of 0.54 and 65% below the Drug Manufacturers industry median of 1.66. Xizang Weixinkang Pharmaceutical Co's overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Xizang Weixinkang Pharmaceutical Co (SHSE:603676), the current PEG Ratio is 0.58 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xizang Weixinkang Pharmaceutical Co (SHSE:603676) Overvalued in 2026?
Based on GuruFocus' analysis, Xizang Weixinkang Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥8.78 is trading 1.7% below its estimated GF Value™ of ¥8.93.
GuruFocus considers Xizang Weixinkang Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:603676:
PEG Ratio: 0.58 (near median its 10-year median of 0.54)
GF Value™: ¥8.93 vs. price of ¥8.78 (1.7% below fair value)
Industry Position: 65% below the Drug Manufacturers median (#54 of 350)
No single metric tells the full story. See the SHSE:603676 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xizang Weixinkang Pharmaceutical Co Business Description
AddressYuanqu South Road, 3rd Floor, Building 4, Industrial Center, No. 5, Zone B, Lhasa Economic and Technological, Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Xizang Weixinkang Pharmaceutical Co Ltd is engaged in research & development, production and sales of chemical pharmaceutical preparations and their raw materials. It also produces and sells liver protection drugs and antibiotic products.
74GF Score
Get the complete analysis for SHSE:603676
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603676 has been successfully added to your 
